169 related articles for article (PubMed ID: 19949929)
1. Drug ratio-dependent antagonism: a new category of multidrug resistance and strategies for its circumvention.
Harasym TO; Liboiron BD; Mayer LD
Methods Mol Biol; 2010; 596():291-323. PubMed ID: 19949929
[TBL] [Abstract][Full Text] [Related]
2. Use of nanoscale delivery systems to maintain synergistic drug ratios in vivo.
Dicko A; Mayer LD; Tardi PG
Expert Opin Drug Deliv; 2010 Dec; 7(12):1329-41. PubMed ID: 21118030
[TBL] [Abstract][Full Text] [Related]
3. Optimization of vincristine-topotecan combination--paving the way for improved chemotherapy regimens by nanoliposomes.
Zucker D; Barenholz Y
J Control Release; 2010 Sep; 146(3):326-33. PubMed ID: 20685223
[TBL] [Abstract][Full Text] [Related]
4. Effect of stealthy liposomal topotecan plus amlodipine on the multidrug-resistant leukaemia cells in vitro and xenograft in mice.
Li X; Lu WL; Liang GW; Ruan GR; Hong HY; Long C; Zhang YT; Liu Y; Wang JC; Zhang X; Zhang Q
Eur J Clin Invest; 2006 Jun; 36(6):409-18. PubMed ID: 16684125
[TBL] [Abstract][Full Text] [Related]
5. Overcoming multidrug resistance in cancer: clinical studies of p-glycoprotein inhibitors.
Coley HM
Methods Mol Biol; 2010; 596():341-58. PubMed ID: 19949931
[TBL] [Abstract][Full Text] [Related]
6. Fluoxetine inhibits multidrug resistance extrusion pumps and enhances responses to chemotherapy in syngeneic and in human xenograft mouse tumor models.
Peer D; Dekel Y; Melikhov D; Margalit R
Cancer Res; 2004 Oct; 64(20):7562-9. PubMed ID: 15492283
[TBL] [Abstract][Full Text] [Related]
7. Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug-resistance efflux pump.
Goren D; Horowitz AT; Tzemach D; Tarshish M; Zalipsky S; Gabizon A
Clin Cancer Res; 2000 May; 6(5):1949-57. PubMed ID: 10815920
[TBL] [Abstract][Full Text] [Related]
8. Nanoparticle-based combination therapy toward overcoming drug resistance in cancer.
Hu CM; Zhang L
Biochem Pharmacol; 2012 Apr; 83(8):1104-11. PubMed ID: 22285912
[TBL] [Abstract][Full Text] [Related]
9. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
10. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
Horowitz NS; Hua J; Gibb RK; Mutch DG; Herzog TJ
Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121
[TBL] [Abstract][Full Text] [Related]
11. In vitro and in vivo characterization of a combination chemotherapy formulation consisting of vinorelbine and phosphatidylserine.
Webb MS; Johnstone S; Morris TJ; Kennedy A; Gallagher R; Harasym N; Harasym T; Shew CR; Tardi P; Dragowska WH; Mayer LD; Bally MB
Eur J Pharm Biopharm; 2007 Mar; 65(3):289-99. PubMed ID: 17123800
[TBL] [Abstract][Full Text] [Related]
12. Reversal of multidrug resistance by two nordihydroguaiaretic acid derivatives, M4N and maltose-M3N, and their use in combination with doxorubicin or paclitaxel.
Chang CC; Liang YC; Klutz A; Hsu CI; Lin CF; Mold DE; Chou TC; Lee YC; Huang RC
Cancer Chemother Pharmacol; 2006 Nov; 58(5):640-53. PubMed ID: 16544145
[TBL] [Abstract][Full Text] [Related]
13. Integrins and extracellular matrix: a novel mechanism of multidrug resistance.
Elliott T; Sethi T
Expert Rev Anticancer Ther; 2002 Aug; 2(4):449-59. PubMed ID: 12647988
[TBL] [Abstract][Full Text] [Related]
14. Increased preclinical efficacy of irinotecan and floxuridine coencapsulated inside liposomes is associated with tumor delivery of synergistic drug ratios.
Harasym TO; Tardi PG; Harasym NL; Harvie P; Johnstone SA; Mayer LD
Oncol Res; 2007; 16(8):361-74. PubMed ID: 17913044
[TBL] [Abstract][Full Text] [Related]
15. Simultaneous delivery of doxorubicin and GG918 (Elacridar) by new polymer-lipid hybrid nanoparticles (PLN) for enhanced treatment of multidrug-resistant breast cancer.
Wong HL; Bendayan R; Rauth AM; Wu XY
J Control Release; 2006 Dec; 116(3):275-84. PubMed ID: 17097178
[TBL] [Abstract][Full Text] [Related]
16. A novel system for evaluation of drug mixtures for potential efficacy in treating multidrug resistant cancers.
Tatosian DA; Shuler ML
Biotechnol Bioeng; 2009 May; 103(1):187-98. PubMed ID: 19137589
[TBL] [Abstract][Full Text] [Related]
17. d,l-buthionine-(S,R)-sulfoximine potentiates in vivo the therapeutic efficacy of doxorubicin against multidrug resistance protein-expressing tumors.
Vanhoefer U; Cao S; Minderman H; Toth K; Skenderis BS; Slovak ML; Rustum YM
Clin Cancer Res; 1996 Dec; 2(12):1961-8. PubMed ID: 9816155
[TBL] [Abstract][Full Text] [Related]
18. Enhanced therapeutic effects on the multi-drug resistant human leukemia cells in vitro and xenograft in mice using the stealthy liposomal vincristine plus quinacrine.
Liang GW; Lu WL; Wu JW; Zhao JH; Hong HY; Long C; Li T; Zhang YT; Zhang H; Wang JC; Zhang X; Zhang Q
Fundam Clin Pharmacol; 2008 Aug; 22(4):429-37. PubMed ID: 18705753
[TBL] [Abstract][Full Text] [Related]
19. Multidrug resistance: clinical relevance in solid tumours and strategies for circumvention.
Kaye SB
Curr Opin Oncol; 1998 Aug; 10 Suppl 1():S15-9. PubMed ID: 9801854
[TBL] [Abstract][Full Text] [Related]
20. Distinctive potentiating effects of cisplatin and/or ifosfamide combined with etoposide in human small cell lung carcinoma xenografts.
Nemati F; Livartowski A; De Cremoux P; Bourgeois Y; Arvelo F; Pouillart P; Poupon MF
Clin Cancer Res; 2000 May; 6(5):2075-86. PubMed ID: 10815935
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
